Overview

CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, as well as drug metabolism/pharmacokinetics (DMPK) expertise.

Utilizing its comprehensive chemistry capabilities, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000 compounds (all compounds designed and synthesized by CGI).  To date, CGI has been awarded 8 U.S. patents covering its novel collection of kinase inhibitors.  Moreover, all three of CGI’s drug discovery and development programs are based on hits obtained from CGI’s library. 

Drug Discovery and Development Programs:

Selective angiogenic kinase inhibitors: Includes cgi1842, an "IND-ready" compound with a unique target profile.

Btk: a critical B-cell kinase. CGI is advancing multiple series of highly selective, proprietary compounds for a broad range of AAID and oncology indications.

Syk: a key regulator of mast cell, monocyte/macrophage, and B-cell function. CGI has identified potent, selective compounds that demonstrate robust oral efficacy in preclinical models.

Founded out of Yale University, CGI (formerly Cellular Genomics Inc.) began operations in 2000.  CGI, in conjunction with several biotech and pharmaceutical partners (Pfizer, Serono, Lilly, Affymetrix, and Schering AG), utilized a unique chemical-genetics approach known as “ASKA” (Analog Sensitive Kinase Alleles) to understand kinase function.  With the completion of those collaborations, CGI out-licensed the ASKA technology to Artemis/Taconic (see http://www.artemispharma.de/news/aska0205en.php).

Over the past 5 years, CGI has built a powerful drug discovery engine that specifically addresses the major challenge associated with kinase targets: selectivity. Integrating its expertise in kinase biology with extensive chemistry and DMPK capabilities, CGI is emerging as a leader in developing selective kinase inhibitor therapeutics for multiple clinical indications.